A Reason Magazine feature follows Bryan Hubbard’s unusual path from conservative Kentucky attorney and public official to one of the country’s most visible advocates for ibogaine research. The article traces how, while leading Kentucky’s Opioid Abatement Advisory Commission, Hubbard became interested in ibogaine as a potential treatment for opioid addiction and began pursuing a plan to direct a portion of opioid settlement funds toward clinical research aimed at eventual FDA approval.
The piece also examines the political and institutional resistance that ultimately halted Kentucky’s proposed ibogaine initiative, as well as Hubbard’s continued efforts to find support in other states. Along the way, the article places his advocacy within the broader debate over addiction treatment, psychedelic medicine, and the challenges of moving a still-illegal compound from anecdotal promise into formal clinical research.